Stimuli-Responsive Therapeutic Metallodrugs

Area of Science:

• Medicinal Chemistry
• Materials Science
• Nanotechnology

Background:

• Platinum-based anticancer drugs have limitations including drug resistance and systemic toxicity.
• Stimuli-responsive metallodrugs offer a promising strategy for site-specific drug delivery, maximizing therapeutic effects and minimizing side effects.
• Metal complexes offer diverse structures and properties for developing novel therapeutic agents.

Purpose of the Study:

• To provide a comprehensive overview of therapeutic stimuli-responsive metallodrugs developed over the past two decades.
• To classify these metallodrugs based on the nature of stimuli (endo-, exo-, and dual-responsive).
• To discuss representative examples, their mechanisms, and potential medical applications, with a focus on platinum and ruthenium complexes.

Main Methods:

• Literature review of stimuli-responsive metallodrugs published in the last 20 years.
• Classification of compounds based on stimuli-responsive mechanisms (redox, pH, enzyme, light, temperature, etc.).
• Analysis of structure-activity relationships and potential therapeutic applications of selected platinum and ruthenium complexes.

Main Results:

• Identification and classification of endo-stimuli-responsive, exo-stimuli-responsive, and dual-stimuli-responsive metallodrugs.
• Detailed discussion of representative platinum and ruthenium complexes, including their design, response mechanisms, and potential anticancer activities.
• Highlighting the progress and diversity in stimuli-responsive metallodrug development.

Conclusions:

• Stimuli-responsive metallodrugs represent a significant advancement in cancer therapy, offering improved targeting and reduced toxicity.
• Platinum and ruthenium complexes are key players in this field, with ongoing research exploring new designs and applications.
• Future research should address challenges in clinical translation and further optimize these sophisticated drug delivery systems.